Adeona, Intrexon Collaborate For Synthetic DNA Therapy for Pulmonary Arterial Hypertension
The Ann Arbor pharmaceutical firm Adeona Pharmaceuticals Inc. and the Human Therapeutics Division of Intrexon Corp., Monday announced the formation of a global exclusive channel collaboration through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon's UltraVector platform and RheoSwitch Therapeutic System for the treatment of pulmonary arterial hypertension.
